期刊文献+

转化生长因子β1及其受体在横纹肌肉瘤中的表达 被引量:5

Expression of transforming growth factor β1 and its receptors in rhabdomyosarcoma
暂未订购
导出
摘要 目的 :探讨横纹肌肉瘤 (RMS)中转化生长因子 β1(TGFβ1)及其Ⅰ、Ⅱ型受体 (TGFβRⅠ ,TGFβRⅡ )表达及其意义。 方法 :应用免疫组化技术 (S P法 )检测 4 9例经电镜或 (和 )免疫组化证实的横纹肌肉瘤及 2 0例正常横纹肌组织中的TGFβ1、TGFβRⅠ和TGFβRⅡ表达水平 ,并结合临床病理资料进行分析。 结果 :TGFβ1在RMS中的高表达率高于正常横纹肌组织 (P<0 0 1) ;TGFβRⅠ、TGFβRⅡ在 98% (48/ 4 9)的RMS及所有正常横纹肌组织中均有表达 ,两组无差异。TGFβ1表达与肌球蛋白重链呈负相关 (r=- 0 6 6 1,P <0 0 1)。TGFβ1在低分化组高表达率为 79% ,高分化组为 38%。 结论 :横纹肌肉瘤中存在TGFβ1自分泌和旁分泌现象 ,且肿瘤细胞表达相关受体。TGFβ1的表达与肌源性分化程度有关。 Purpose To investigate the expression of TGFβ1,and its receptorsⅠ, Ⅱ (TGFβRⅠ,TGFβRⅡ) in rhabdomyosarcoma (RMS), and their relationship with clinicopathological features. Methods Immunohistochemical technique(S P) was used to detect the expression of TGFβ1, TGFβRⅠ,RⅡ and myosin in 49 cases of rhabdomyosarcoma and 20 normal skeletal muscles. Results Increased expression of TGFβ1 was found in RMS compared with normal skeletal muscle ( P <0 01). Expression of TGFβ RⅠ and RⅡ were detected in most of RMSs and all of normal skeletal muscles without significant difference.There was a close negative correlation between the expression of TGFβ1 and myosin ( r =-0 661, P <0 01). Overexpression of TGFβ1 was oberserved in the low differentiated group more frequently than that in the high differentiated one. Conclusions There are TGFβ1 autocrine/paracrine pathway in RMS,with the expression of TGFβ1 associated receptors.Expression of TGFβ1 is related to the degree of myogenic differentiation of RMS. Overexpression of TGFβ1 may play a role in development and progression of rhabdomyosarcoma.
出处 《临床与实验病理学杂志》 CAS CSCD 2002年第1期61-64,共4页 Chinese Journal of Clinical and Experimental Pathology
基金 纽约中华医学基金会 (CMB)基金资助项目 (No 0 0 72 2 )
关键词 横纹肌肉瘤 转化生长因子Β1 受体 免疫组织化学 rhabdomyosarcoma transforming growth factor β receptors,transforming growth factor β immunohistochemistry
  • 相关文献

参考文献14

  • 1[1]Wong SF, Lai LC. The role of TGFbeta in human cancers. Pathology, 2001;33:85~92
  • 2[2]Bouche M, Canipari R, Melchinna R et al. TGF-β autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cell. Faseb J, 2000;14:1147~58
  • 3[3]Romeo DS, Mizdl SB. Partial purification of an immunosuppressive protein from a human tumor cell line and analysis of its relationship to transforming growth factor beta. Cell Immunol, 1989;122:483~92
  • 4[4]Molennar WM, Oosterhuis JW, Kamps WA. Cytologic"differentiation" in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol, 1984;15:973~9
  • 5[5]Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell, 2000;103:295~309
  • 6[6]Wrana JL, Attisano L, Wieser R et al. Mechanism of activation of the TGFβ receptor. Nature, 1994;370:341~7
  • 7[7]Markowitz S, Wang J, Myeroff L et al. Inactivation of the type Ⅱ TGF-beta receptor in colon cancer cells with micro-satellite instability. Science, 1995;268:1336~8
  • 8[8]McCune BK, Patterson K, Chandra RS et al. Expression of transforming growth factor-beta isoform in small round cell tumors of childhood. Am J Pathol, 1993;142:49~58
  • 9[9]Ignotz RA, Massague J. Type β transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc Natl Acad Sci USA, 1985;82:530~4
  • 10[10]Olson EN, Sternberg E, Hu JS et al. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol, 1986;103:1799~805

同被引文献53

  • 1[1]Djaborkhel R, Tvrdik D, Eckschlager T, et al. Cyclin A downregulation in TGFbeta1-arrested follicular lymphoma cells [J].Exp Cell Res, 2000, 261(1):250~259
  • 2[2]Liu X, Sun Y, Ehrlich M, et al. Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kipl mislocalization [J]. Oncogene, 2000, 19(51):5926~5935
  • 3[3]Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma[J]. Cancer, 2001, 92(12):2985~2992
  • 4[4]Ramont L, Pasco S, Homebeck W, et al. Transforming growth factor-betal inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system [J]. Exp Cell Rcs, 2003, 291(1):1~10
  • 5[5]de Caestecker MP, Piek E, Roberts B, et al. Role of transforming growth factor-β signaling in cancer [J]. J Natl Cancer Inst, 2000,92(17):1388~1402
  • 6[6]Turco A, Scarpa S, Coppa A, et al. Increased TGF-beta type 1Ⅱreceptor expression suppresses the malignant phenotype and induces difffrentiation of human neuroblastoma cells [J]. Exp Cell Res, 2000, 25(1):77~85
  • 7[7]Inman GJ, Allday MJ. Resistance to TGF-betal correlates with a reduction of TGF-beta type Ⅱ receptor expression in Burkitt′s lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines[J].J Gen Virol, 2000, 81(Pt 6):1567~1578
  • 8[8]Yanagisawa K, Uchida K, Nagatake M, et al. Heterogeneities in the biological and biochemical fi nctions of Smad2 and Smad4mutants naturally occurring in human lung cancers [J].Oncogene, 2000, 19(19):2305~2311
  • 9[9]Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactive transforming growth factor beta signaling by targeting smads to the ubiqutin-proteasome pathway [J]. Proc Natl Acad Sci USA, 2000, 97(9):4820~4825
  • 10[10]Tanaka S, Mori M, Mafune K, et al. A dominant negative mutation of transforming factor-beta receptor type ц gene in microsatellite stable oesophageal carcinoma[J]. BrJ Cancer, 2000, 82:(9) 1557~1560

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部